{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,29]],"date-time":"2025-06-29T01:22:36Z","timestamp":1751160156228},"reference-count":37,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1S","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,12]]},"abstract":"\n Background and aims<\/jats:title>\n Sorafenib, used for advanced-stage hepatocellular carcinoma (HCC), has an overall survival (OS) of 10 months. However, some patients have better response and long-term survival (LTS). Aims to assess predictive factors for LTS.<\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n Retrospectively reviewed 77 advanced HCC patients, starting sorafenib treatment between 2007 and 2016, with LTS (OS \u226524 months) as primary endpoint. Univariate and multivariable analysis of clinical variables were performed in order to identify predictive factors for LTS.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n Patients: seventy (90.9%) males; median age: 65 years (39\u201382). All had cirrhosis mostly HCV infection (n<\/jats:italic> = 32, 41.6%). Majority were Child-Pugh class A (n<\/jats:italic> = 50, 64.9%); median MELD-Na: 11 (6\u201330). Multinodular HCC: 74% (n<\/jats:italic> = 57); portal vein invasion (PVI): 50.6% (n<\/jats:italic> = 39); extrahepatic spread: 18.2% (n<\/jats:italic> = 14). Median time between HCC diagnosis and sorafenib start: 3.3 months (0\u201337.6). Median OS: 13 months [95% confidence interval (CI) 8.2\u201317.8]. Twenty-five (32.5%) patients were considered LTS, with amedian OS: 52.3 months (95% CI 17.1\u201387.4). Multivariable analysis identified Child-Pugh class A [odds ratio (OR) 11.1, 95% CI 1.78\u201369.54] and absence of PVI (OR 7.88, 95% CI 1.56\u201339.8) as independent predictors of LTS. Sub-analysis of Child-Pugh class A: absence of PVI (OR 7.13, 95% CI 1.69\u201330.2) and alpha-fetoprotein <400\u2009ng\/ml (OR 5.82, 95% CI 1.18\u201328.75) independently related to LTS.<\/jats:p>\n <\/jats:sec>\n \n Conclusion<\/jats:title>\n Despite global short median OS, sorafenib treatment is associated with longer than 2-year survival in a sub-group, more likely in compensated liver disease and absence of PVI.<\/jats:p>\n <\/jats:sec>","DOI":"10.1097\/meg.0000000000001974","type":"journal-article","created":{"date-parts":[[2020,11,11]],"date-time":"2020-11-11T18:00:13Z","timestamp":1605117613000},"page":"e114-e120","update-policy":"http:\/\/dx.doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":3,"title":["Predictive factors for long-term survival in patients with advanced hepatocellular carcinoma treated with sorafenib"],"prefix":"10.1097","volume":"33","author":[{"given":"Daniela","family":"Reis","sequence":"first","affiliation":[{"name":"Servi\u00e7o de Gastrenterologia e Hepatologia, Hospital de Santa Maria, Centro Hospitalar Universit\u00e1rio Lisboa Norte EPE"}]},{"given":"Miguel","family":"Moura","sequence":"additional","affiliation":[{"name":"Servi\u00e7o de Gastrenterologia e Hepatologia, Hospital de Santa Maria, Centro Hospitalar Universit\u00e1rio Lisboa Norte EPE"}]},{"given":"Lu\u00eds Carlos","family":"Freitas","sequence":"additional","affiliation":[{"name":"Servi\u00e7o de Gastrenterologia e Hepatologia, Hospital de Santa Maria, Centro Hospitalar Universit\u00e1rio Lisboa Norte EPE"}]},{"given":"Sofia","family":"Carvalhana","sequence":"additional","affiliation":[{"name":"Servi\u00e7o de Gastrenterologia e Hepatologia, Hospital de Santa Maria, Centro Hospitalar Universit\u00e1rio Lisboa Norte EPE"}]},{"given":"Paulo Jorge","family":"Nogueira","sequence":"additional","affiliation":[{"name":"Laborat\u00f3rio de Biomatem\u00e1tica, Faculdade de Medicina, Universidade de Lisboa"}]},{"given":"Raquel","family":"Gaio","sequence":"additional","affiliation":[{"name":"Servi\u00e7o de Imagiologia, Hospital de Santa Maria, Centro Hospitalar Lisboa Norte EPE"}]},{"given":"Rui Tato","family":"Marinho","sequence":"additional","affiliation":[{"name":"Servi\u00e7o de Gastrenterologia e Hepatologia, Hospital de Santa Maria, Centro Hospitalar Universit\u00e1rio Lisboa Norte EPE"},{"name":"Cl\u00ednica Universit\u00e1ria de Gastrenterologia, Faculdade de Medicina da Universidade de Lisboa"}]},{"given":"Helena","family":"Cortez-Pinto","sequence":"additional","affiliation":[{"name":"Servi\u00e7o de Gastrenterologia e Hepatologia, Hospital de Santa Maria, Centro Hospitalar Universit\u00e1rio Lisboa Norte EPE"},{"name":"Cl\u00ednica Universit\u00e1ria de Gastrenterologia, Faculdade de Medicina da Universidade de Lisboa"},{"name":"Laborat\u00f3rio de Nutri\u00e7\u00e3o, Faculdade de Medicina, Universidade de Lisboa, Lisboa, Portugal"}]}],"member":"276","published-online":{"date-parts":[[2020,11,10]]},"reference":[{"key":"R1-20240821","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1111\/liv.12818","article-title":"Global patterns of hepatocellular carcinoma management from diagnosis to death: the BRIDGE Study.","volume":"35","author":"Park","year":"2015","journal-title":"Liver Int"},{"key":"R2-20240821","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1016\/j.jhep.2018.11.029","article-title":"Sorafenib with or without concurrent transarterial chemoembolization in patients with advanced hepatocellular carcinoma: the phase III STAH trial.","volume":"70","author":"Park","year":"2019","journal-title":"J Hepatol"},{"key":"R3-20240821","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1002\/hep.29913","article-title":"Diagnosis, staging, and management of hepatocellular carcinoma: 2018 practice guidance by the American Association for the study of liver diseases.","volume":"68","author":"Marrero","year":"2018","journal-title":"Hepatology"},{"key":"R4-20240821","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/S1470-2045(08)70284-5","article-title":"Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis.","volume":"10","author":"Mazzaferro","year":"2009","journal-title":"Lancet Oncol"},{"key":"R5-20240821","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1016\/j.jhep.2019.08.006","article-title":"Impact of combined selective internal radiation therapy and sorafenib on survival in advanced hepatocellular carcinoma.","volume":"71","author":"Ricke","year":"2019","journal-title":"J Hepatol"},{"key":"R6-20240821","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1080\/0284186X.2020.1759826","article-title":"The value of sorafenib trough levels in patients with advanced hepatocellular carcinoma \u2013 a substudy of the SORAMIC trial.","volume":"59","author":"Labeur","year":"2020","journal-title":"Acta Oncol (Madr)"},{"key":"R7-20240821","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1056\/NEJMoa0708857","article-title":"Sorafenib in advanced hepatocellular carcinoma.","volume":"359","author":"Llovet","year":"2008","journal-title":"N Engl J Med"},{"key":"R8-20240821","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S1470-2045(08)70285-7","article-title":"Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.","volume":"10","author":"Cheng","year":"2009","journal-title":"Lancet Oncol"},{"key":"R9-20240821","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.jhep.2018.03.019","article-title":"EASL clinical practice guidelines: management of hepatocellular carcinoma.","volume":"69","author":"Galle","year":"2018","journal-title":"J Hepatol"},{"issue":"Suppl 4","key":"R10-20240821","doi-asserted-by":"crossref","first-page":"iv238","DOI":"10.1093\/annonc\/mdy308","article-title":"Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.","volume":"29","author":"Vogel","year":"2018","journal-title":"Ann Oncol"},{"key":"R11-20240821","doi-asserted-by":"crossref","first-page":"4067","DOI":"10.1200\/JCO.2012.45.8372","article-title":"Sunitinib versus sorafenib in advanced hepatocellular cancer: results of a randomized phase III trial.","volume":"31","author":"Cheng","year":"2013","journal-title":"J Clin Oncol"},{"key":"R12-20240821","doi-asserted-by":"crossref","first-page":"2889","DOI":"10.1200\/JCO.2009.25.9895","article-title":"Advanced hepatocellular carcinoma: which staging systems best predict prognosis?","volume":"28","author":"Huitzil-Melendez","year":"2010","journal-title":"J Clin Oncol"},{"key":"R13-20240821","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1093\/annonc\/mdt072","article-title":"Sorafenib combined with transarterial chemoembolization for the treatment of advanced hepatocellular carcinoma: a large-scale multicenter study of 222 patients.","volume":"24","author":"Zhao","year":"2013","journal-title":"Ann Oncol"},{"key":"R14-20240821","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1002\/hep.29668","article-title":"Patients with advanced hepatocellular carcinoma need a personalized management: a lesson from clinical practice.","volume":"67","author":"Giannini","year":"2018","journal-title":"Hepatology"},{"key":"R15-20240821","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1038\/s41416-019-0488-4","article-title":"Using prognostic and predictive clinical features to make personalised survival prediction in advanced hepatocellular carcinoma patients undergoing sorafenib treatment.","volume":"121","author":"Berhane","year":"2019","journal-title":"Br J Cancer"},{"key":"R16-20240821","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.jpge.2016.04.006","article-title":"Tratamento de Carcinoma Hepatocelular Com Sorafenib: avalia\u00e7\u00e3o de Fatores de Progn\u00f3stico e um Ind\u00edcio Pr\u00e1tico para a Orienta\u00e7\u00e3o dos Doentes.","volume":"23","author":"Cardoso","year":"2016","journal-title":"Ge Port J Gastroenterol"},{"key":"R17-20240821","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1002\/hep.20636","article-title":"Prognosis of hepatocellular carcinoma: comparison of 7 staging systems in an American cohort.","volume":"41","author":"Marrero","year":"2005","journal-title":"Hepatology"},{"key":"R18-20240821","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1016\/S0140-6736(18)30010-2","article-title":"Hepatocellular carcinoma.","volume":"391","author":"Forner","year":"2018","journal-title":"Lancet"},{"key":"R19-20240821","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1097\/MEG.0b013e3283386053","article-title":"Tolerance and outcome of patients with unresectable hepatocellular carcinoma treated with sorafenib.","volume":"22","author":"Ozenne","year":"2010","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"R20-20240821","doi-asserted-by":"crossref","first-page":"5293","DOI":"10.1002\/cncr.27543","article-title":"The use of single-agent sorafenib in the treatment of advanced hepatocellular carcinoma patients with underlying Child-Pugh B liver cirrhosis: a retrospective analysis of efficacy, safety, and survival benefits.","volume":"118","author":"Chiu","year":"2012","journal-title":"Cancer"},{"key":"R21-20240821","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1007\/s00280-011-1616-x","article-title":"Sorafenib for hepatocellular carcinoma according to Child-Pugh class of liver function.","volume":"68","author":"Kim","year":"2011","journal-title":"Cancer Chemother Pharmacol"},{"key":"R22-20240821","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1016\/j.jhep.2012.06.014","article-title":"Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: subanalyses of a phase III trial.","volume":"57","author":"Bruix","year":"2012","journal-title":"J Hepatol"},{"key":"R23-20240821","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1016\/j.jhep.2017.06.026","article-title":"Prognostic factors and predictors of sorafenib benefit in patients with hepatocellular carcinoma: Analysis of two phase III studies.","volume":"67","author":"Bruix","year":"2017","journal-title":"J Hepatol"},{"key":"R24-20240821","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1111\/liv.12168","article-title":"Clinical parameters predictive of outcomes in sorafenib-treated patients with advanced hepatocellular carcinoma.","volume":"33","author":"Cho","year":"2013","journal-title":"Liver Int"},{"key":"R25-20240821","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1111\/liv.12591","article-title":"Clinical features associated with radiological response to sorafenib in unresectable hepatocellular carcinoma: a large multicenter study in Japan.","volume":"35","author":"Takeda","year":"2015","journal-title":"Liver Int"},{"key":"R26-20240821","doi-asserted-by":"crossref","first-page":"2816","DOI":"10.1002\/cam4.1493","article-title":"Prognosis of patients with hepatocellular carcinoma treated with sorafenib: a comparison of five models in a large Canadian database.","volume":"7","author":"Samawi","year":"2018","journal-title":"Cancer Med"},{"key":"R27-20240821","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1097\/MEG.0b013e32834bd2d0","article-title":"A single center experience of sorafenib in advanced hepatocellular carcinoma patients: evaluation of prognostic factors.","volume":"23","author":"Song","year":"2011","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"R28-20240821","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1002\/hep.23485","article-title":"A meta-analysis of survival rates of untreated patients in randomized clinical trials of hepatocellular carcinoma.","volume":"51","author":"Cabibbo","year":"2010","journal-title":"Hepatology"},{"key":"R29-20240821","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1001\/archsurg.2010.295","article-title":"Evaluation of absolute serum \u03b1-fetoprotein levels in liver transplant for hepatocellular cancer.","volume":"146","author":"Mailey","year":"2011","journal-title":"Arch Surg"},{"key":"R30-20240821","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1097\/MEG.0000000000000558","article-title":"Prognosis of advanced hepatocellular carcinoma: a new stratification of Barcelona Clinic Liver Cancer stage C: results from a French multicenter study.","volume":"28","author":"Adhoute","year":"2016","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"R31-20240821","first-page":"259","article-title":"Relationship of ethnicity and overall survival in patients treated with sorafenib for advanced hepatocellular carcinoma.","volume":"5","author":"Peixoto","year":"2014","journal-title":"J Gastrointest Oncol"},{"key":"R32-20240821","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1002\/hep.24644","article-title":"Field-practice study of sorafenib therapy for hepatocellular carcinoma: a prospective multicenter study in Italy.","volume":"54","author":"Iavarone","year":"2011","journal-title":"Hepatology"},{"key":"R33-20240821","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1007\/s12072-010-9249-4","article-title":"Safety and tolerance of sorafenib in Japanese patients with advanced hepatocellular carcinoma.","volume":"5","author":"Ogasawara","year":"2011","journal-title":"Hepatol Int"},{"key":"R34-20240821","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1007\/s10637-015-0237-3","article-title":"Sorafenib treatment in Child-Pugh A and B patients with advanced hepatocellular carcinoma: safety, efficacy and prognostic factors.","volume":"33","author":"Ogasawara","year":"2015","journal-title":"Invest New Drugs"},{"key":"R35-20240821","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1159\/000342650","article-title":"Efficacy, safety, and survival factors for sorafenib treatment in Japanese patients with advanced hepatocellular carcinoma.","volume":"84","author":"Nakano","year":"2013","journal-title":"Oncology"},{"key":"R36-20240821","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/S0140-6736(18)30207-1","article-title":"Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.","volume":"391","author":"Kudo","year":"2018","journal-title":"Lancet"},{"key":"R37-20240821","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","article-title":"Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma.","volume":"382","author":"Finn","year":"2020","journal-title":"N Engl J Med"}],"container-title":["European Journal of Gastroenterology & Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MEG.0000000000001974","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,22]],"date-time":"2024-08-22T22:04:51Z","timestamp":1724364291000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MEG.0000000000001974"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,10]]},"references-count":37,"journal-issue":{"issue":"1S","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1097\/meg.0000000000001974","relation":{},"ISSN":["0954-691X"],"issn-type":[{"type":"print","value":"0954-691X"}],"subject":[],"published":{"date-parts":[[2020,11,10]]}}}